What is the ticker symbol for Arcus Biosciences?

Arcus Biosciences trades under the ticker RCUS on NYSE.

What sector does Arcus Biosciences operate in?

Arcus Biosciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze RCUS in a portfolio?

PortView shows RCUS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Arcus Biosciences (RCUS) Stock Analysis

NYSEHealthcareBiotechnology

$29.56-0.50%

1-year price historyRange $11.32 – $31.57

52-week range$29.56

$10.72$31.74

What Arcus Biosciences does

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Key metrics

Market cap

$3.72B

P/E (TTM)

-7.58

EPS (TTM)

$-3.90

Beta

0.81

Dividend yield

0.00%

Revenue / share

$0.93

50-day avg

$29.14

200-day avg

$24.47

52-week high

$31.74

52-week low

$10.72

CEO

Terry J. Rosen

ETFs linked to RCUS

Broad-market and Healthcare sector ETFs an investor holding Arcus Biosciences is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how RCUS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze RCUS in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Arcus Biosciences?: Arcus Biosciences trades under the ticker RCUS on NYSE.
Which exchange is RCUS listed on?: RCUS is listed on NYSE.
What sector does Arcus Biosciences operate in?: Arcus Biosciences is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze RCUS in a portfolio?: PortView shows RCUS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.